AKT1 and head and neck squamous cell carcinoma: Numerous studies have suggested that both EGCG and erlotinib significantly inhibit p-EGFR, p-ERK and p-AKT in SCCHN and that this is associated with a marked increase in apoptosis [38,40,41].